Notice for vorasidenib citrate (Servier Laboratories (Aust) Pty Ltd)
Active ingredients
vorasidenib citrate
Date of review outcome
Lapse date
Type
Priority Review
Indication
Treatment of predominantly non-enhancing astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH-1) mutation or isocitrate dehydrogenase-2 (IDH-2) mutation in adults and paediatric patients 12 years and older following surgical intervention
Therapeutic area
Oncology